Zipcode Bio Receives Grant to Advance HIV and Malaria mRNA Vaccines

BOSTON, Sep. 17, 2025 – Zipcode Bio, a U.S. biotechnology company pioneering next-generation nucleic acid therapeutics, today announced it has received a grant from the Gates Foundation. The funding will support the development of mRNA vaccines for HIV and malaria using the company’s proprietary SHARP™ nanoparticle delivery and AI platform, with the goal of producing safe, effective, and affordable vaccines that can be scaled globally.

“Funding support from the foundation is a pivotal milestone for Zipcode Bio,” said Dr. Jason Zhang, Co-Founder and CEO. “This award enables us to advance vaccines that are not only scientifically innovative but also practical, scalable, and accessible to communities that need them most. By targeting HIV and malaria, we are addressing diseases that continue to cause immense human suffering and disproportionately affect underserved populations.”

Zipcode Bio’s SHARP™ technology is designed to enhance vaccine durability, reduce cold-chain requirements, and broaden access in resource-limited settings. If successful, these vaccines could represent a major step toward equitable access to life-saving immunizations in regions where traditional vaccine technologies face challenges in distribution, cost, and infrastructure, particularly in low- and middle-income countries.

About Zipcode Bio
Zipcode Bio is a U.S. biotechnology company focused on next-generation nucleic acid therapeutics. Co-founded by Dr. Jason Zhang and Dr. Drew Weissman—the 2023 Nobel Laureate in Physiology or Medicine—the company applies cutting-edge RNA expertise to address critical unmet medical needs. Zipcode Bio’s proprietary SHARP™ technology delivers nucleic acid therapeutics efficiently to specific tissues with streamlined manufacturing, improved efficacy, and enhanced safety. With a team dedicated to innovation and precision, Zipcode Bio is developing groundbreaking therapeutics to improve healthcare and shape the future of medicine.